BACKGROUND: Calprotectin is potentially a more sensitive biomarker of disease activity in rheumatoid arthritis (RA) than conventional acute-phase proteins such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) because it directly reflects inflammation in the synovium and synovial fluid rather than systemic inflammatory activity. OBJECTIVE: The aim of this study was to evaluate relationships between serum calprotectin levels, disease activity, and response to treatment. Calprotectin was also investigated as a predictive marker of clinical response. METHODS: This observational study included selected cohorts of patients with RA treated at La Paz University Hospital, Madrid, Spain. Associations between serum calprotectin levels and clinical and laboratory parameters were analyzed in a cross-sectional cohort of 60 patients with varying disease activity, and changes in calprotectin levels in response to treatment with infliximab were analyzed at baseline and after 3 and 6 months of treatment in a longitudinal cohort of 20 patients with very active disease. RESULTS: In the cross-sectional cohort, calprotectin levels correlated with rheumatoid factor levels (r = 0.25; p < 0.05) but not with titers of antibodies to cyclic citrullinated peptide. Significant correlations were also observed between calprotectin levels and the 28 swollen joint count (28-SJC), Disease Activity Score based on a 28-joint count (DAS28), Simplified Disease Activity Index (SDAI), ESR, and CRP levels. In the longitudinal cohort, calprotectin levels at baseline were not predictive of response to treatment but significantly decreased during treatment in responders (p < 0.0001). CONCLUSION: Calprotectin levels strongly correlate with clinical and laboratory assessments of joint inflammation and also decrease in response to treatment, indicating that calprotectin is a promising marker for assessment and monitoring of disease activity in patients with RA. Investigations are required to further evaluate its diagnostic, prognostic, and therapeutic potential.
BACKGROUND: Calprotectin is potentially a more sensitive biomarker of disease activity in rheumatoid arthritis (RA) than conventional acute-phase proteins such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) because it directly reflects inflammation in the synovium and synovial fluid rather than systemic inflammatory activity. OBJECTIVE: The aim of this study was to evaluate relationships between serum calprotectin levels, disease activity, and response to treatment. Calprotectin was also investigated as a predictive marker of clinical response. METHODS: This observational study included selected cohorts of patients with RA treated at La Paz University Hospital, Madrid, Spain. Associations between serum calprotectin levels and clinical and laboratory parameters were analyzed in a cross-sectional cohort of 60 patients with varying disease activity, and changes in calprotectin levels in response to treatment with infliximab were analyzed at baseline and after 3 and 6 months of treatment in a longitudinal cohort of 20 patients with very active disease. RESULTS: In the cross-sectional cohort, calprotectin levels correlated with rheumatoid factor levels (r = 0.25; p < 0.05) but not with titers of antibodies to cyclic citrullinated peptide. Significant correlations were also observed between calprotectin levels and the 28 swollen joint count (28-SJC), Disease Activity Score based on a 28-joint count (DAS28), Simplified Disease Activity Index (SDAI), ESR, and CRP levels. In the longitudinal cohort, calprotectin levels at baseline were not predictive of response to treatment but significantly decreased during treatment in responders (p < 0.0001). CONCLUSION: Calprotectin levels strongly correlate with clinical and laboratory assessments of joint inflammation and also decrease in response to treatment, indicating that calprotectin is a promising marker for assessment and monitoring of disease activity in patients with RA. Investigations are required to further evaluate its diagnostic, prognostic, and therapeutic potential.
Authors: N M Wulffraat; P J Haas; M Frosch; I M De Kleer; T Vogl; D M C Brinkman; P Quartier; J Roth; W Kuis Journal: Ann Rheum Dis Date: 2003-03 Impact factor: 19.103
Authors: J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell Journal: Rheumatology (Oxford) Date: 2003-02 Impact factor: 7.580
Authors: Burkhard F Leeb; Ingrid Andel; Judith Sautner; Mirela Bogdan; Adil Maktari; Thomas Nothnagl; Bernhard Rintelen Journal: Arthritis Rheum Date: 2005-02-15
Authors: Erik R Vossenaar; Suzanne Nijenhuis; Monique M A Helsen; Annemarie van der Heijden; Tatsuo Senshu; Wim B van den Berg; Walther J van Venrooij; Leo A B Joosten Journal: Arthritis Rheum Date: 2003-09
Authors: Carle Ryckman; Shaun R McColl; Karen Vandal; Rinaldo de Médicis; André Lussier; Patrice E Poubelle; Philippe A Tessier Journal: Arthritis Rheum Date: 2003-08
Authors: Jana Hurnakova; Hana Hulejova; Jakub Zavada; Martin Komarc; Lucie Andres Cerezo; Herman Mann; Jiri Vencovsky; Karel Pavelka; Ladislav Senolt Journal: Clin Rheumatol Date: 2018-04-14 Impact factor: 2.980
Authors: Jana Hurnakova; Jakub Zavada; Petra Hanova; Hana Hulejova; Martin Klein; Herman Mann; Olga Sleglova; Marta Olejarova; Sarka Forejtova; Olga Ruzickova; Martin Komarc; Jiri Vencovsky; Karel Pavelka; Ladislav Senolt Journal: Arthritis Res Ther Date: 2015-09-15 Impact factor: 5.156
Authors: José Inciarte-Mundo; Julio Ramirez; Maria Victoria Hernández; Virginia Ruiz-Esquide; Andrea Cuervo; Sonia Raquel Cabrera-Villalba; Mariona Pascal; Jordi Yagüe; Juan D Cañete; Raimon Sanmarti Journal: Arthritis Res Ther Date: 2016-07-08 Impact factor: 5.156